Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cipla Signals US Launch Momentum, Commodity-Like Price Cycle

Executive Summary

Cipla's US business appears set to gain momentum with a string of differentiated generic launches lined up and the firm's CEO shares key insights into how price peaks and troughs could potentially play out in the world's largest pharmaceutical market.


Related Content

Cipla Primes For US Momentum But Seretide Generic Is Slow In UK
Asia Executives To Watch: Novartis China, GSK India, Cipla
Pfizer, Cipla Pledge Better Access To Affordable Cancer Therapies In Africa
Cipla, Sandoz Gearing For Seretide Challenge In Australia?
India’s Pricing Tussle Escalates After Regulator Names “Overcharging” Firms
Cipla Sees Changed Profile; Wraps Up Europe Revamp


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts